CLGN
CollPlant Biotechnologies Ltd.
CLGN trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CLGN overall, supported by stronger fundamentals and stronger valuation.
CLGN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
CLGN's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CLGN PE Valuation
CLGN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CLGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CLGN's losses to shrink, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CLGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.39 | +$1.91 |
| Q1 2026 | -$10.30 | +$1.90 |
| Q4 2025 | -$9.30 | +$5.30 |
| Q3 2025 | -$10.20 | +$5.10 |
| Q2 2025 | -$11.30 | +$4.00 |
| Q1 2025 | -$12.20 | -$5.50 |
| Q4 2024 | -$14.60 | -$8.10 |
| Q3 2024 | -$15.30 | -$9.20 |
CLGN is still losing money, but far less than before: $9.39 per share over the past year, against $21.40 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CLGN on earnings quality, reporting a profit while its opponent remains loss making.
CLGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $108K | -40% |
| Q1 2026 | $73K | -96% |
| Q4 2025 | $60K | -63% |
| Q3 2025 | $77K | +1825% |
| Q2 2025 | $179K | -28% |
| Q1 2025 | $2.1M | +1997% |
| Q4 2024 | $164K | -45% |
| Q3 2024 | $4K | -91% |
CLGN's revenue has slid since its 2021 peak: $108,000 last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2438% | -663 points |
| Q1 2026 | -4267% | -4187 points |
| Q4 2025 | -5250% | -2827 points |
| Q3 2025 | -4555% | +108995 points |
| Q2 2025 | -1775% | -5.9 points |
| Q1 2025 | -80% | +4337 points |
| Q4 2024 | -2423% | -728 points |
| Q3 2024 | -113550% | -102848 points |
CLGN's operating margin was −2438% last quarter, down 663 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CLGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CLGN on profitability, with a higher operating margin.
CLGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.5M | -$99K |
| Q1 2026 | -$3.1M | -$1.9M |
| Q4 2025 | -$3.2M | +$296.9K |
| Q3 2025 | -$2.9M | +$710K |
| Q2 2025 | -$2.4M | +$1.7M |
| Q1 2025 | -$1.2M | +$2.2M |
| Q4 2024 | -$3.5M | -$949K |
| Q3 2024 | -$3.6M | -155% |
CLGN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CLGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +67.9K shares |
| 1 year | +22% | +259K shares |
| 3 years | +22% | +265K shares |
| 5 years | +41% | +423K shares |
| Available history | +209% | +976K shares |
CLGN has 1M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CLGN hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CLGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CLGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -9.1x | Net Cash |
| Q3 2021 | -11.9x | Net Cash |
| Q2 2021 | -2.5x | Net Cash |
| Q1 2021 | -2.5x | Net Cash |
CLGN has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CLGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 23.1 | Neutral |
CLGN's weekly RSI is 50 (neutral) and its Stochastic is 23 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CLGN PE vs Healthcare Sector
CLGN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CLGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 19% above |
| 20 week MA | $3.63 | 28% above |
| 50 week MA | $6.53 | 29% below |
| 100 week MA | $16.3 | 72% below |
| 200 week MA | $39.0 | 88% below |
CLGN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 88% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CLGN on trend strength, trading above more of its moving averages.
CLGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.0 | $100.5 | +73% |
| 2021 | $100.5 | $132.2 | +32% |
| 2022 | $132.2 | $83.4 | -37% |
| 2023 | $83.4 | $63.9 | -23% |
| 2024 | $63.9 | $35.7 | -44% |
| 2025 | $35.7 | $15.3 | -57% |
| 2026 YTD | $15.3 | $4.64 | -70% |
CLGN has finished four years in a row lower, and it's down 70% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CLGN on returns for 2026, with the stronger performance.